Clinical Trials Browser

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Brain Neoplasms, Soft Tissue Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Melanoma, Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Melanoma, Neoplasm Metastasis

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Advanced KRAS Positive Metastatic Colorectal Cancer

Solid Tumors Harboring a BRAF V600 Mutation

Colorectal Neoplasms

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Colorectal Neoplasms

Multiple Myeloma, Recurrence

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Colorectal Neoplasms

Gastrointestinal Stromal Tumors

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Noonan Syndrome 5, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Advanced Solid Tumor

Advanced Solid Tumors

Biliary Tract Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Biliary Tract Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Advanced and Selected Solid Tumors

Clinical Trials

COLUMBUS

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Study of MEK162 for Children With Low-Grade Gliomas

MEK162

MK3475-C01

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

EBRAIN-MEL

NF108-BINI

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

KEYNOTE-651

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers

SECOMBIT

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

LOGIC-2

ANCHOR-CRC

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

BEACON CRC

GMMG-BIRMA

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

MErCuRIC1

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

SIGNATURE

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer

MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors